



Drug Utilization Review Board Recommendations December 4, 2014

The Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review (DUR) Board has conducted its clinical and financial evaluations and provided its recommendations for the Department of Community Health's (DCH) final decisions on the following drug reviews for the Georgia Medicaid FFS) Preferred Drug List (PDL) at the DUR Board Meeting held on December 4, 2014. The recommendations on new drug reviews as well as class reviews are highlighted below. Current PDL status is located at <http://dch.georgia.gov/preferred-drug-lists>.

New Drug Reviews

Antihemophilic

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Eloctate*[®] (*Intravenous*) *Vial*.

Allergen Immunotherapy

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Grastek*[®] (*Sublingual*) *Tablet*, *Oralair*[®] (*Sublingual*) *Tablet* and *Ragwitek*[®] (*Sublingual*) *Tablet*.

Lysosomal Storage Disorder

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Myalept*[®] (*Subcutaneous*) *Vial*.

Antineoplastic

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Zykadia*[®] (*Oral*) *Capsule*.

Sedative Hypnotic

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Hetlioz*[®] (*Oral*) *Capsule*.

Class Reviews

Sedative Hypnotics

The DUR Board recommended *No Changes*.

Granulocyte Colony Stimulating Factors

The DUR Board recommended *No Changes*.